We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Marinus Pharmaceuticals (MRNS) Stock Jumps 8.4%: Will It Continue to Soar?
Read MoreHide Full Article
Marinus Pharmaceuticals (MRNS - Free Report) shares soared 8.4% in the last trading session to close at $8.01. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 8.8% gain over the past four weeks.
The rise in share price is attributable to positive investor expectations for Marinus’ sole marketed drug Ztalmy (ganaxolone) approved by the FDA for the treatment of seizures associated with CDKL5 deficiency disorder in patients two years of age and older. The drug is also being evaluated in other indications like status epilepticus, tuberous sclerosis complex and lennox-gastaut syndrome.
This epilepsy drug developer is expected to post quarterly loss of $0.77 per share in its upcoming report, which represents a year-over-year change of -48.1%. Revenues are expected to be $5.33 million, down 62.5% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Marinus Pharmaceuticals, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on MRNS going forward to see if this recent jump can turn into more strength down the road.
Marinus Pharmaceuticals belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Pacira (PCRX - Free Report) , closed the last trading session 1.9% higher at $43.27. Over the past month, PCRX has returned 7.5%.
Pacira's consensus EPS estimate for the upcoming report has changed -1.1% over the past month to $0.60. Compared to the company's year-ago EPS, this represents a change of -6.3%. Pacira currently boasts a Zacks Rank of #5 (Strong Sell).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Marinus Pharmaceuticals (MRNS) Stock Jumps 8.4%: Will It Continue to Soar?
Marinus Pharmaceuticals (MRNS - Free Report) shares soared 8.4% in the last trading session to close at $8.01. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 8.8% gain over the past four weeks.
The rise in share price is attributable to positive investor expectations for Marinus’ sole marketed drug Ztalmy (ganaxolone) approved by the FDA for the treatment of seizures associated with CDKL5 deficiency disorder in patients two years of age and older. The drug is also being evaluated in other indications like status epilepticus, tuberous sclerosis complex and lennox-gastaut syndrome.
This epilepsy drug developer is expected to post quarterly loss of $0.77 per share in its upcoming report, which represents a year-over-year change of -48.1%. Revenues are expected to be $5.33 million, down 62.5% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Marinus Pharmaceuticals, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on MRNS going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Marinus Pharmaceuticals belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Pacira (PCRX - Free Report) , closed the last trading session 1.9% higher at $43.27. Over the past month, PCRX has returned 7.5%.
Pacira's consensus EPS estimate for the upcoming report has changed -1.1% over the past month to $0.60. Compared to the company's year-ago EPS, this represents a change of -6.3%. Pacira currently boasts a Zacks Rank of #5 (Strong Sell).